GNSZ News interview with Dr. Craig Dionne, PhD, Ge
Post# of 88914
Posted On: 08/06/2014 9:23:14 AM
GNSZ News interview with Dr. Craig Dionne, PhD, GenSpera CEO
GenSpera's CEO Shares Insight on Unique Properties and Targeting of Lead Drug G-202, Based on the Thapsigargin Toxin
http://finance.yahoo.com/news/gensperas-ceo-s...00390.html
POINT ROBERTS, Wash. and NEW YORK, Aug. 5, 2014 /PRNewswire/
Investorideas.com, a global news source covering leading sectors including biotech, issues an exclusive Q&A interview with Dr. Craig Dionne, PhD, GenSpera's (GNSZ) CEO. Dr. Dionne discusses the company's lead drug G-202 and how they have taken a powerful toxin named thapsigargin to selectively target and kill cancer cells.
GenSpera's CEO Shares Insight on Unique Properties and Targeting of Lead Drug G-202, Based on the Thapsigargin Toxin
http://finance.yahoo.com/news/gensperas-ceo-s...00390.html
POINT ROBERTS, Wash. and NEW YORK, Aug. 5, 2014 /PRNewswire/
Investorideas.com, a global news source covering leading sectors including biotech, issues an exclusive Q&A interview with Dr. Craig Dionne, PhD, GenSpera's (GNSZ) CEO. Dr. Dionne discusses the company's lead drug G-202 and how they have taken a powerful toxin named thapsigargin to selectively target and kill cancer cells.
(0)
(0)Scroll down for more posts ▼